sábado, 13 de febrero de 2021

Statement—Four Potential COVID-19 Therapeutics Enter Phase 2/3 Testing in NIH ACTIV-2 Trial | NIH: National Institute of Allergy and Infectious Diseases

Statement—Four Potential COVID-19 Therapeutics Enter Phase 2/3 Testing in NIH ACTIV-2 Trial | NIH: National Institute of Allergy and Infectious Diseases
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)